Skip to main content

04-06-2019 | Castration-sensitive prostate cancer | Video | Article

Researcher comment: OS boost with enzalutamide in metastatic CSPC setting

Christopher Sweeney presents the main findings of the ENZAMET trial, which evaluated the impact of supplementing androgen deprivation therapy with enzalutamide in men with advanced castration-sensitive prostate cancer (3:10).

Image Credits